Point72 Asset Management
BLTE

Point72 Asset Management’s Belite Bio BLTE Stock Holding History

Point72 Asset Management’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.88M Buy
+51,186
New +$7.85M 0.01% 1437
2026
Q1 		– Sell
-284,437
Closed -$45.5M – 3804
2025
Q4 		$45.5M Buy
284,437
+281,337
+9,075% +$33.3M 0.05% 448
2025
Q3 		$229K Buy
3,100
+1,800
+138% +$118K ﹤0.01% 2111
2025
Q2 		$75K Buy
+1,300
New +$79.3K ﹤0.01% 2088
2024
Q4 		– Sell
-4,800
Closed -$225K – 2092
2024
Q3 		$225K Sell
4,800
-2,511
-34% -$122K ﹤0.01% 1765
2024
Q2 		$334K Sell
7,311
-1,389
-16% -$60.1K ﹤0.01% 1521
2024
Q1 		$334K Buy
8,700
+1,000
+13% +$44.8K ﹤0.01% 1753
2023
Q4 		$352K Buy
+7,700
New +$296K ﹤0.01% 1664

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management's BLTE Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Belite Bio (BLTE) in Q2 2026: 51,186 shares worth $7.88M. The stake represents 0.01% of the portfolio and ranks #1437 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in BLTE as recently as Q4 2025.

Point72 Asset Management first reported a position in BLTE in Q4 2023 and has held it in 8 quarters since. The position peaked at $45.5M in Q4 2025. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Point72 Asset Management held 51,186 shares of Belite Bio worth $7.88M as of Q2 2026.
  • Belite Bio was a new Point72 Asset Management position in Q2 2026.
  • Belite Bio made up 0.01% of Point72 Asset Management's portfolio in Q2 2026, its #1437 holding.
  • Point72 Asset Management first reported a position in Belite Bio in Q4 2023 and has held it in 8 quarters since.
  • Point72 Asset Management's Belite Bio position peaked at $45.5M in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.